In 2023, Paul Lonergan faced a prolonged sore throat mystery, leading to a startling discovery of a sizable tumor near his tongue base after extensive medical consultations in Toronto. Lonergan embarked on a challenging journey of seven weeks of radiation and chemotherapy, battling in and out of the intensive care unit to eradicate his tumor completely.
Following his treatment, Lonergan questioned if his cancer was truly cured. Through a clinical trial, he underwent a “liquid biopsy,” a modern method utilizing blood tests to detect hidden traces of tumor DNA undetectable through traditional scans. Surprisingly, the test revealed ongoing tumor fragments in his bloodstream, indicating a potential recurrence risk.
Subsequently, Lonergan underwent experimental immunotherapy and has remained cancer-free, as confirmed by subsequent liquid biopsies monitoring his bloodstream for any signs of the disease. Despite the restricted availability of this cancer monitoring technique in Canada, there is optimism for broader access in the future.
Dr. Ramy Saleh from McGill University Health Centre hailed liquid biopsies as a revolutionary tool for disease surveillance, potentially transforming how clinicians monitor cancer recurrence. A Toronto-based team has initiated a vast research project, SHERLOCK, to explore the integration of this technology into routine patient care, aiming to enhance cancer survivor protection and reduce unnecessary treatments.
The ongoing five-year clinical trial led by University Health Network in Toronto plans to offer liquid biopsies to over 7,000 patients who have undergone traditional cancer treatments, to detect circulating tumor DNA indicating possible cancer recurrence. Dr. Lillian Siu, the lead researcher, emphasized the project’s focus on early disease detection through blood testing, promoting timely curative interventions for patients.
Despite the promising prospects of liquid biopsies, Dr. Christopher Booth from Queen’s University raised ethical concerns regarding informing cancer survivors about potential residual disease. He highlighted the psychological burden faced by patients receiving such information, emphasizing the importance of responsible implementation of this technology.
The evolving liquid biopsy technology, although promising, requires ongoing research to optimize its efficacy and reliability for various cancer types. While there have been advancements in liquid biopsy techniques, challenges such as false positives and false negatives persist, underscoring the need for continuous refinement and validation.
Amidst growing interest and excitement surrounding liquid biopsies, the cost and coverage challenges remain significant barriers in the Canadian healthcare system. Dr. Saleh emphasized the need for evidence demonstrating cost-effectiveness and improved patient outcomes to facilitate broader adoption of this innovative technology in cancer care.
As the UHN clinical trial progresses towards its conclusion in 2031, Dr. Siu remains hopeful that the study will provide invaluable insights into the potential of liquid biopsies in cancer management, paving the way for routine use and widespread benefits for patients in Canada and beyond.
